gene set enrichment analysis biocarta signaling pathway signatures Search Results


gene set enrichment analysis biocarta signaling pathway signatures  (BioCarta)
90
BioCarta gene set enrichment analysis biocarta signaling pathway signatures
( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the <t>BioCarta</t> <t>signatures</t> (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.
Gene Set Enrichment Analysis Biocarta Signaling Pathway Signatures, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/pmc04947904-157-15-15
Average 90 stars, based on 1 article reviews
gene set enrichment analysis biocarta signaling pathway signatures - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

Journal: Scientific Reports

Article Title: Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features

doi: 10.1038/srep29915

Figure Lengend Snippet: ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

Article Snippet: The underlying mechanisms of the discovered modules were revealed by gene set enrichment analysis using BioCarta signaling pathway signatures .

Techniques: Labeling